The neurobiological research program has generated genuinely important findings, though they have not yet delivered on the promise of resolving the classification debate. Human neuroimaging studies have identified overlap between sexual arousal circuitry and reward regions implicated in substance-related addiction. Preclinical models have demonstrated morphological changes in nucleus accumbens circuitry following repeated sexual behavior — including increased dendritic spine density — in patterns that parallel reward-sensitization findings in stimulant exposure models.
The dopaminergic pharmacology of Parkinson’s disease provides one of the most methodologically clean lines of evidence in this area. The well-documented emergence of new-onset compulsive sexual behavior in patients receiving dopamine agonist therapy constitutes a pharmacological model demonstrating that dopaminergic modulation of CSBD-relevant circuitry is achievable through defined mechanisms. This finding has influenced both the neurobiological research agenda and clinical practice in neurological dosing management.
Genetic research has identified associations between long-repeat alleles of the D4 dopamine receptor gene (DRD4) and traits including novelty-seeking, impulsivity, and risk-taking sexual behavior — the same alleles implicated in ADHD, alcoholism, and financial risk-taking. This suggests a shared genetic diathesis for impulsive and sensation-seeking behavioral profiles rather than a CSBD-specific genetic substrate.
Against these advances, an equally honest accounting of limitation is required. No validated neurobiological marker currently exists that reliably distinguishes CSBD from normative high sexual drive. Early diffusion tensor imaging work in small samples demonstrated inconclusive findings regarding white matter organization in frontal regions. The neuroimaging evidence base is limited by small sample sizes, heterogeneous patient populations, and the absence of standardized diagnostic criteria across studies.
Reward-circuit overlap does not establish addiction status. Sexual behavior, eating, gambling, exercise, and social interaction all engage reward circuitry. The neurobiological evidence is associative, not mechanistically definitive, and should not be communicated — in clinical settings or teaching contexts — as though it resolves the addiction-versus-impulse-control debate.
The field also faces a significant sex-differentiation gap. The majority of neurobiological research has been conducted in male subjects. Sex-differentiated activation patterns have been observed, but the implications for CSBD phenomenology and diagnosis in women remain substantially unknown. The generalizability of neurobiological findings to female, LGBTQ+, and non-Western populations is a significant open question that the field has not adequately addressed.
The Parkinson’s dopamine agonist finding — new-onset compulsive sexual behavior and gambling in patients without prior disorder history — represents the most methodologically rigorous pharmacological evidence for dopaminergic involvement in CSBD. Its clinical implication: dopaminergic modulation in at-risk individuals can precipitate CSBD, and dopamine agonist dose management is a meaningful clinical lever in neurological populations. DRD4 long-repeat allele associations suggest that CSBD shares genetic risk architecture with other impulse-dysregulation conditions rather than possessing a disorder-specific genetic substrate. This has treatment implications: comorbid ADHD, substance use, and other impulse-control conditions in CSBD populations may reflect shared underlying diathesis rather than coincidence, and comprehensive comorbidity assessment is clinically essential. The sex-differentiation gap in neurobiological research has direct clinical consequences. Female presentations of CSBD may involve qualitatively different behavioral phenotypes, neurobiological mechanisms, and functional consequences than the predominantly male samples in which current knowledge was generated. Clinicians should apply current neurobiological knowledge to female patients with explicit epistemic caution.